Forma Therapeutics Inc.

Novo Nordisk acquired its pyruvate kinase-R (PKR) activator etavopivat when it bought Forma Therapeutics for $1.1bn to expand its portfolio in rare hemoglobinopathies outside of hemophilia. At the Ame

The relentless expansion of Pharma’s R&D pipeline was checked somewhat last year, even as the proportion of drugs in active development for cancer reached new heights, and the burgeoning industry in A

The US FDA approved two standard review novel agent last week, albeit with distinct profiles: a new therapeutic approach offering the first approved therapy for a stubborn unmet medical need, and a ta

Christmas has come early for Rigel Pharmaceuticals, Inc. with US regulators giving the green light to Rezlidhia a couple of months sooner than expected but the US firm is all set to make the acute m